Antibody · 림프종

90개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved90 programs
AntibodyLimited DatastaleMarcela V. Maus, M.D.,Ph.D.Phase 2

Emapalumab (Emapalumab)

Large B-cell Lymphoma; Relapsed Non-Hodgkin Lymphoma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#LargeB-cellLymphoma+2
Trials 29Status Recruiting
AntibodyCurated CorestaleRegeneron PharmaceuticalsPhase 3

Odronextamab (Odronextamab)

Relapsed/Refractory Aggressive B-Cell Lymphoma · B-cell Non Hodgkin Lymphoma

#B-cellNonHodgkinLymphoma#Antibody#Phase3#BioJungboMoa-pick#monoclonal-antibody+3
Trials 18Status Recruiting
AntibodyLimited DatastaleKite, A Gilead CompanyPhase 1

Utomilumab (Utomilumab)

Relapsed/Refractory Large B-cell Lymphoma · HER2

#HER2#Antibody#Phase1#monoclonal-antibody#Relapsed+2
Trials 17Status Active
AntibodyLimited DatastaleRochePhase 2

90Yttrium-Ibritumomab Tiuxetan (Zevalin®, 90Yttrium-Ibritumomab Tiuxetan, 90Yttrium-Ibritumomab Tiuxetan (Zevalin®)+Rituximab)

Follicular Lymphoma · Follicular Lymphoma

#FollicularLymphoma#Antibody#Phase2#monoclonal-antibody#Roche
Trials 16Status Active
AntibodyLimited DatastaleBristol-Myers SquibbPhase 2

Lirilumab (Lirilumab)

Non-Hodgkin's Lymphoma; Hodgkin Lymphoma · Squamous Cell Carcinoma of the Head and

#SquamousCellCarcinomaoftheHeadan#Antibody#Phase2#monoclonal-antibody#Non-HodgkinsLymphoma+2
Trials 13Status Active
AntibodyLimited DatastaleInnoventPhase 2

Sintilimab+Pegaspargase (Sintilimab+Pegaspargase)

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type · Natural Killer/T-Cell Lymphoma, Nasal an

#NaturalKillerT-CellLymphomaNasal#Antibody#Phase2#monoclonal-antibody#NaturalKiller+3
Trials 8Status Recruiting
AntibodyLimited DatastaleKite, A Gilead CompanyPhase 1

Lenzilumab (Lenzilumab)

Relapsed/Refractory Large B-cell Lymphoma · FRα

#FR#Antibody#Phase1#monoclonal-antibody#Relapsed+2
Trials 6Status Discontinued
AntibodyLimited DatastaleActinium PharmaceuticalsPhase 1

131-I Apamistamab (131-I Apamistamab)

B-ALL; DLBCL · B-ALL

#B-ALL#Antibody#Phase1#monoclonal-antibody#DLBCL+1
Trials 4Status Recruiting
AntibodyLimited DatastaleRochePhase 2

131I-rituximab (131I-rituximab)

Relapsed or Refractory Follicular Lymphoma or Mantle Cell Lymphoma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#RelapsedorRefractoryFollicularLy+1
Trials 4Status Active
AntibodyLimited DatastaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab [TECENTRIQ])

Neoplasms · Lymphoma

#Lymphoma#Antibody#Phase2#monoclonal-antibody#Neoplasms+1
Trials 4Status Active
AntibodyLimited DatastaleHoffmann-La RochePhase 2

Rituxumab (Rituxumab)

B-cell Non-Hodgkin Lymphoma · B-cell Non-Hodgkin Lymphoma

#B-cellNon-HodgkinLymphoma#Antibody#Phase2#monoclonal-antibody#Hoffmann-La
Trials 4Status Active
AntibodyLimited DatastaleGenentech, Inc.Phase 2

Bispecific antibody-based combined with CAR-T cell therapy (Bispecific antibody-based combined with CAR-T cell therapy)

B-cell Non-Hodgkin Lymphoma · B-cell Non-Hodgkin Lymphoma

#B-cellNon-HodgkinLymphoma#Antibody#Phase2#monoclonal-antibody#Genentech
Trials 3Status Recruiting
AntibodyLimited DatastaleAmgenPhase 2

MT103 (Blinatumomab, Blinatumomab (MT103))

Non-Hodgkin's Lymphoma, Relapsed · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#Antibody#Phase2#monoclonal-antibody#Non-HodgkinsLymphoma+2
Trials 2Status Active
AntibodyLimited DatastalePeking UniversityPhase 2

Dexamethasone, azacytidine, Pegaspargase, Tislelizumab (Dexamethasone, azacytidine, Pegaspargase, Tislelizumab)

NK/T Cell Lymphoma · NK/T Cell Lymphoma

#NKTCellLymphoma#Antibody#Phase2#monoclonal-antibody#NK+2
Trials 2Status Active
AntibodyLimited DatastalePETHEMA FoundationPhase 2

ibritumomab tiuxetan (ibritumomab tiuxetan)

Lymphoma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#Lymphoma+1
Trials 2Status Discontinued
AntibodyLimited DatastaleMaisonneuve-Rosemont HospitalPhase 2

Zevalin (90Y ibritumomab tiuxetan, 90Y ibritumomab tiuxetan (Zevalin))

Non-Hodgkins Lymphoma · Non-Hodgkins Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase2#monoclonal-antibody#Maisonneuve-Rosemont
Trials 1Status Active
AntibodyLimited DatastaleSun Yat-sen UniversityPhase 2

Adebrelimab & SHR2554 (Adebrelimab & SHR2554)

Relapsed or Refractory Peripheral T Cell Lymphoma; NKTCL · FRα

#FR#Antibody#Phase2#monoclonal-antibody#RelapsedorRefractoryPeripheralTC+2
Trials 1Status Recruiting
AntibodyLimited DatastaleGoethe UniversityPhase 2

MabCampath (Alemtuzumab, Alemtuzumab (MabCampath))

Adult Acute Lymphocytic Leukemia T-cell; Lymphoma, Lymphoblastic · Adult Acute Lymphocytic Leukemia T-cell

#AdultAcuteLymphocyticLeukemiaT-c#Antibody#Phase2#monoclonal-antibody#Lymphoma+2
Trials 1Status Active
AntibodyLimited DatastaleGlaxoSmithKlinePhase 2

Tositumomab and Iodine I 131 Tositumomab (Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody, Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab))

Lymphoma, Non-Hodgkin · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#monoclonal-antibody#Lymphoma+2
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

Anti-PD-1 Antibody Plus Chidamide and Rituximab (Anti-PD-1 Antibody Plus Chidamide and Rituximab)

Relapsed or Refractory DLBCL · PD-1

#PD-1#Antibody#Phase2#monoclonal-antibody#RelapsedorRefractoryDLBCL+1
Trials 1Status Active

2 / 5 pages

← PreviousNext →